![Thomas Spitznagel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Spitznagel
Corporate Officer/Principal presso MACROGENICS, INC.
Patrimonio netto: 34 012 $ in data 31/05/2024
Posizioni attive di Thomas Spitznagel
Società | Posizione | Inizio | Fine |
---|---|---|---|
MACROGENICS, INC. | Corporate Officer/Principal | 01/01/2013 | - |
Storia della carriera di Thomas Spitznagel
Precedenti posizioni note di Thomas Spitznagel
Società | Posizione | Inizio | Fine |
---|---|---|---|
Human Genome Sciences, Inc.
![]() Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 01/03/1998 | 01/07/2012 |
Nabi Biopharmaceuticals
![]() Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Direttore Tecnico/Scientifico/R&S | 01/01/1998 | 01/01/1998 |
Genetics Institute LLC
![]() Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/1996 | 01/01/1996 |
Formazione di Thomas Spitznagel
Massachusetts Institute of Technology | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 7 |
Posizioni
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 1 |
Undergraduate Degree | 1 |
Settori
Health Technology | 5 |
Finance | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
MACROGENICS, INC. | Health Technology |
Aziende private | 3 |
---|---|
Human Genome Sciences, Inc.
![]() Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Nabi Biopharmaceuticals
![]() Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Health Technology |
Genetics Institute LLC
![]() Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Thomas Spitznagel
- Esperienza